← ANALYST RATINGS · TIPRANKS
Nkarta (NKTX): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $11.75, the highest $14.00, the lowest $10.00. The average is +552.8% from the last price of $1.80.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.00 | Sell | +11.1% | Downgrade | 16.10.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.00 | Sell | +11.1% | Downgrade | 16.10.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.00 | Sell | +11.1% | Downgrade | 16.10.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.00 | Sell | +11.1% | Downgrade | 16.10.26on TipRanks 03:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.50 → $2.00−20.0% | Hold | +11.1% | Reiterated | 14.10.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.50 → $2.00−20.0% | Hold | +11.1% | Reiterated | 08.10.26on TipRanks 03:05 | — | |
| Gil Blum★★★★★★★★★★#949 · hits 43% · avg +12.5% | Needham | $11.00 | Buy | +511.1% | Reiterated | 05.10.26on TipRanks 07:14 | −2.4%next day −9.2% · 5 days −14.7% | ↗ |
| Stephen Willey★★★★★★★★★★#1608 · hits 45% · avg +8.1% | Stifel Nicolaus | $10.00 | Buy | +455.6% | Reiterated | 28.09.26on TipRanks 06:55 | −2.2%next day −1.7% · 5 days −6.4% | ↗ |
| Emily Bodnar★★★★★★★★★★#2140 · hits 39% · avg +7.2% | H.C. Wainwright | $14.00 | Buy | +677.8% | Reiterated | 21.09.26on TipRanks Sep 22 05:45 | +0.2%next day +2.4% · 5 days −6.3% | ↗ |
| Salim Syed★★★★★★★★★★#7609 · hits 44% · avg +0.2% | Mizuho Securities | $12.00 | Buy | +566.7% | Reiterated | 17.08.26on TipRanks 12:10 | +4.8%next day −0.1% · 5 days +7.8% | ↗ |
| Phil Nadeau★★★★★★★★★★#1350 · hits 48% · avg +8.7% | TD Cowen | — | Buy | — | Reiterated | 10.08.26on TipRanks Aug 11 02:45 | +2.1%next day −5.0% · 5 days −1.2% | ↗ |
| Jonathan Miller★★★★★★★★★★#10361 · hits 41% · avg −3.3% | Evercore ISI | $25.00 → $9.00−64.0% | Buy | +400.0% | Reiterated | 18.05.26on TipRanks 08:45 | +1.6%next day +0.7% · 5 days +12.6% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Nkarta
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $11.75 at a price of $2.62 (+348.5%); now: $11.75 at $1.80 (+552.8%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 8 | 5 | 5 | 6 | 7 |
| Buy | 1 | 1 | 1 | 2 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.40 (from $-0.53 to $-0.30). Last quarter: $-0.54.
Best top-analyst consensus in the sector · Healthcare
About Nkarta
- CEO: Paul J. Hastings
- Employees: 106
- 1150 Veterans Boulevard, South San Francisco, CA, 94080, US
- www.nkartatx.com
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Data from the stock’s TipRanks forecast page, read 53 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗